The participation of renal expression of CD80 and CD86 in the immunopathogenesis of crescentic Th1-mediated antiglomerular basement membrane (anti-GBM) glomerulonephritis (GN) has not been assessed. Immunohistochemical staining demonstrated prominent upregulation of both molecules in glomeruli of mice with anti-GBM GN, suggesting a potential role for the local expression of CD80 and CD86 in nephritogenic effector T cell responses. For testing this hypothesis, control or inhibitory anti-CD80 and/or anti-CD86 mAb were administered to mice during the effector phase of the disease but after the establishment of a systemic immune response. Anti-CD80 or anti-CD86 mAb treatment had no effect on the development of GN or infiltration of leukocytes into glomeruli; however, administration of anti-CD80/86 mAb attenuated glomerular accumulation of CD4؉ T cells and macrophages, crescent formation, and proteinuria, correlating with reduced antigenspecific skin delayed-type hypersensitivity. Attenuated glomerular infiltration of leukocytes in mice that were treated with anti-CD80/86 mAb was associated with decreased intraglomerular expression of adhesion molecules P-selectin and intercellular adhesion molecule-1, as well as attenuated renal mRNA levels of proinflammatory cytokines IFN-␥ and migration inhibitory factor, without reducing chemokine and chemokine receptor expression in the kidney or intraglomerular apoptosis and proliferation. The systemic Th1/Th2 balance (assessed by splenocyte production of IFN-␥ and IL-4 and circulating levels of IgG1 and IgG2a) was not affected by the inhibition of CD80 and CD86. These studies show that CD80 and CD86 are expressed in glomeruli of mice with crescentic anti-GBM GN, in which they play a critical role in facilitating accumulation of Th1 effectors and macrophages, thus exacerbating renal injury.
G lomerulonephritis (GN) is characterized by intraglomerular inflammation and is a major cause of endstage renal failure. The most severe and rapidly progressive type of GN is crescentic nephritis. Most of the knowledge about the immunopathogenesis of crescentic GN comes from experimental models. The best characterized and most widely used model of crescentic GN is anti-glomerular basement membrane (anti-GBM) globulin GN, in which heterologous anti-GBM antibody (Ab) acts as a planted antigen (Ag) in glomeruli. The development of crescentic GN in this model occurs in two phases. During the induction phase, animals are sensitized to a foreign heterologous globulin. The effector phase is initiated in the kidney by challenging sensitized animals with heterologous anti-mouse GBM globulin. It is mediated by infiltrating CD4ϩ Th1 cells that direct recruitment of macrophages (1) (2) (3) , attenuated by Th2 cytokines (4, 5) , and is independent of the deposited autologous Ab (6) . Similarly, the development of human crescentic GN is thought to be mediated by CD4ϩ Th1 cells and macrophages that are invariably present in glomeruli of patients with the disease (7) .
CD4ϩ T cells require a co-stimulatory signal in addition to T cell receptor engagement for full activation. CD80 (B7-1) and CD86 (B7-2) are the two major co-stimulatory ligands for T cells. They are commonly expressed by Ag-presenting cells, including macrophages, but can also be upregulated on nonlymphoid cells at inflammatory sites (8) . The interaction between these molecules and T cell receptors CD28 and CTLA-4 promotes or downregulates T cell responses, respectively (8 -10) .
CD80 and CD86 play a major role in the initiation of numerous T cell-mediated diseases, such as experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis, by affecting naïve T cell activation, proliferation, and survival, as well as Th1/Th2 differentiation (11) (12) (13) . However, the role of these molecules in the effector immune responses in vivo is much less clear. CD80 and CD86 have been shown to be present in target organs of several immune-mediated diseases, including EAE and experimental autoimmune thyroiditis (EAT) (14, 15) , in which they have been demonstrated to play a role in effector immune responses when pathogenic T cells infiltrate target tissues and mediate disease. For example, adoptive transfer of sensitized encephalitogenic T cells into CD80/86Ϫ/Ϫ mice markedly attenuated EAE (11) . Similarly, inhibition of CD80 and CD86 after the onset of clinical signs of collageninduced arthritis ameliorated disease (13) , and blockade of these molecules in recipients of previously sensitized splenocytes suppressed the development of EAT (14) . CD80 and CD86 have been shown to be critically important during the initiation of several models of GN, including experimental autoimmune glomerulonephritis, lupus nephritis, renal allograft rejection, and anti-GBM globulin GN (16 -22) . In contrast, the role of these molecules in the local effector immune responses that induce GN is much less clear. It has been shown that co-stimulation provided by CD80 and CD86 in the kidney can play a critical role in the effector functions of infiltrating T cells and macrophages. In a rat model of chronic renal allograft rejection, blockade of CD28/B7 co-stimulation late after the onset of graft injury attenuated intragraft accumulation of T cells and macrophages and improved graft function (23) . However, the contribution of renal expression of CD80 and CD86 to nephritogenic T cell effector immune responses that induce crescentic GN is unknown. The expression of CD80 and/or CD86 has been demonstrated in glomeruli of mice (21) and humans with crescentic GN (24) , suggesting that these molecules have the potential to play a role in the effector phase of the disease and that blocking them might have therapeutic potential. The current studies demonstrate, for the first time, that CD80 and CD86 are upregulated in glomeruli of mice with crescentic anti-GBM GN, in which they enhance glomerular accumulation of Th1 effectors and macrophages and exacerbate disease.
Materials and Methods

Experimental Design
Animals. Eight-to 10-wk-old male mice were used for experiments. C57BL/6 mice were obtained from Monash University Animal Services (Melbourne, Australia).
Induction of Accelerated Anti-GBM GN. Mice were sensitized by a subcutaneous injection of 0.5 mg of normal sheep globulin in Freund's complete adjuvant (day 0). Sheep anti-mouse GBM globulin was given intravenously at a dose of 14 mg/mouse (day 10). Immune responses and renal injury were assessed on day 20. mAb Treatment. Each mouse received 100 g of protein G-purified inhibitory hamster anti-mouse CD80 (16-10A1) and/or rat antimouse CD86 (GL1) mAb or control Ab (hamster and/or rat IgG) intraperitoneally. 16-10A1 and GL1 hybridomas were provided by Dr. David Tarlinton (Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia). Treatment was started on day 10 and repeated on days 12, 14, 16, and 18. Mice that were developing GN received the following Ab treatments:
• Anti-CD80 mAb (n ϭ 7) versus guinea pig IgG (n ϭ 7); • Anti-CD86 mAb (n ϭ 10) versus rat IgG (n ϭ 6);
• Anti-CD80 and anti-CD86 (anti-CD80/86) mAb (n ϭ 7) versus guinea pig and rat IgG (n ϭ 5).
The anti-CD80/86 experiment was repeated because it produced statistically significant results (control IgG n ϭ 6; anti-CD80/86 n ϭ 6); however, representative data from only one experiment are presented because similar results were obtained from both experiments. Nonimmunized mice (n ϭ 8) provided normal controls without GN.
Renal Expression of CD80 and CD86
CD80 and CD86 were detected by immunohistochemistry. Frozen kidney sections (6 m thick) from nondiseased controls and mice with GN were blocked with the biotin blocking system (DAKO, Carpinteria, CA), followed by 10% normal mouse serum or 10% normal rabbit serum in 5% BSA/PBS. Hamster anti-mouse CD80 (16-10A1) and rat anti-mouse CD86 (GL1) mAb were used to detect CD80 and CD86. Kidney sections from CD80Ϫ/Ϫ and CD86Ϫ/Ϫ mice with GN, as well as isotype-matched control IgG (hamster IgG or rat IgG2a; Pharmingen, San Diego, CA), served as negative controls. Sections were incubated with biotinylated mouse anti-hamster IgG (Pharmingen) or biotinylated rabbit anti-rat IgG (DAKO), after which they were blocked with 0.3% H 2 O 2 in methanol for 5 min. StreptABComplex/HRP (DAKO) was added for 30 min, after which slides were developed with diaminobenzidine and counterstained with hematoxylin.
Double immunofluorescence was performed on 6-m-thick frozen kidney sections to determine which glomerular cells express CD80 and CD86. Macrophages were detected with FA/11 Ab conjugated to Alexa-488 (American Type Culture Collection [ATCC], Manassas, VA), endothelial cells with anti-von Willebrand factor mAb conjugated to Alexa-488 (Cedar Lane, ON, Canada), and glomerular mesangial cells with anti-smooth muscle actin mAb conjugated to Alexa-488 (Sigma, St. Louis, MO). CD80 and CD86 were detected with anti-CD80 (16-10A1) and CD86 Ab (GL1) both conjugated to Alexa-594 (Molecular Probes, Orlando, FL). Ab against CD80 or CD86 and the three different cell types (macrophages or endothelial or mesangial) were added together (on the same sections) and incubated at 37°C for 40 min.
Renal Injury
Crescent formation was assessed on periodic acid-Schiff reagentstained, Bouin's-fixed 3-m-thick paraffin sections. Glomeruli were considered to be crescentic when two or more cell layers were observed in Bowman's space. At least 50 glomeruli/animal were counted to determine the percentage of crescent formation. Proteinuria (mg/24 h) was measured by a modified Bradford's method on urine collected during the final 24 h of experiments.
Glomerular Macrophages and CD4ϩ T Cells
Macrophages and CD4ϩ T cells were demonstrated by immunoperoxidase staining of periodate-lysine paraformaldehyde-fixed frozen 6-m-thick kidney sections, as described previously (3, 25) , using FA/11 (rat anti-mouse macrosialin; ATCC) for macrophages and GK1.5 mAb (rat anti-mouse CD4; ATCC) for CD4ϩ T cells. Isotype-matched control IgG (rat IgG2b; Pharmingen) served as a negative control. A minimum of 20 glomeruli/animal were assessed, and results were expressed as cells per glomerular cross-section (c/gcs).
Circulating Ag-Specific Ab Levels
Serum Ag-specific IgG1 (1:500 dilution) and IgG2a (1:50 dilution) levels were assessed by ELISA as described previously (26) , using horseradish peroxidase-conjugated goat anti-mouse IgG1 (Southern Biotechnology Association, Birmingham, AL) and biotinylated rat antimouse IgG2a (Pharmingen). Results are expressed as the mean OD 450 Ϯ SEM. Sera from nonimmunized mice provided baseline Ab levels. DMEM (10% FCS) in the presence of 10 g/ml sheep globulin for 72 h. Concentrations of IFN-␥ and IL-4 in splenocyte supernatants were measured by ELISA, as described previously (4), using rat anti-mouse IFN-␥ (Pharmingen), biotinylated rat anti-mouse IFN-␥ (Pharmingen), rat anti-mouse IL-4 (11B11; ATCC), and biotinylated rat anti-mouse IL-4 (BVD6; DNAX, Palo Alto, CA). A minimum of six samples were in each group for each experiment, and each splenocyte sample was from a different mouse.
Skin Delayed-Type Hypersensitivity
Mice received an intradermal injection in the right hind foot pad of 0.5 mg of normal sheep globulin in 30 l of PBS 24 h before the end of experiments. Normal horse globulin was injected into the left foot pad as a control Ag. After 24 h, skin delayed-type hypersensitivity (DTH) was quantified by measuring the difference in foot pad thickness (in mm) using a micrometer.
Renal Expression of P-Selectin and Intercellular Adhesion
Molecule-1 P-selectin and intercellular adhesion molecule-1 (ICAM-1) were identified in 6-m-thick frozen kidney sections by immunofluorescence. Sections were blocked with 10% normal rat serum (ICAM-1) or 10% normal sheep serum (P-selectin) in 5% BSA/PBS. ICAM-1 was detected with PE-conjugated rat anti-mouse ICAM-1 (Pharmingen). For P-selectin, sections were incubated with polyclonal rabbit anti-human P-selectin Ab that cross-reacts with mouse P-selectin (gift from Dr. Michael C. Berndt, Monash University, Clayton, Victoria, Australia) followed by FITC-conjugated sheep anti-rabbit IgG (DakoCytomation, Glostrup, Denmark). Intraglomerular P-selectin and ICAM-1 expression was scored from 0 to 3 as follows: 0, background staining; 1, very low positive staining; 2, moderate positive staining; 3, very strong positive staining. A minimum of 20 glomeruli/animal were assessed to determine the average score.
Renal mRNA Expression of Cytokines, Chemokines, and Chemokine Receptors
Renal mRNA expression of cytokines (IFN-␥, macrophage migration inhibitory factor [MIF] , and IL-1␤; custom mouse cytokine template), chemokines (RANTES, macrophage inflammatory protein-1␣ [MIP-1␣], MIP-1␤, IP-10, monocyte chemoattractant protein [MCP-1], and T cell activation protein-3 [TCA-3]; template set mCK-5c), and chemokine receptors (CCR1, CCR2, CCR5, and CXCR3; template set mCR-5 including template for CXCR3) was measured by RNase protection assay as described previously (27) using Pharmingen's RiboQuant system. The results (mRNA levels) are expressed as arbitrary units (AU) relative to the housekeeping gene, L32.
Intraglomerular Apoptosis
Apoptotic cells were detected in periodate-lysine paraformaldehydefixed 6-m-thick kidney sections on day 20 by transferase-mediated dUTP nick-end labeling (TUNEL) staining using an in situ cell death detection kit according to the manufacturer's instructions (Roche Diagnostics, Penzberg, Germany). Briefly, sections were blocked with 1% H 2 O 2 /methanol and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. They then were incubated with TUNEL reaction mixture (containing terminal deoxynucleotidyl transferase and fluoresceinlabeled nucleotides) at 37°C for 1 h, after which they were blocked with 10% normal sheep serum in 5% BSA/PBS. Converter-POD (containing horseradish peroxidase-conjugated sheep anti-fluorescein Ab) then was incubated at 37°C for 30 min, after which sections were developed with diaminobenzidine and counterstained with hematoxylin. A minimum of 20 glomeruli/animal were examined to determine the average number of TUNELϩ (apoptotic) cells (based on positive staining and typical apoptotic morphology) per gcs.
Intraglomerular Proliferation
Proliferating cells were identified in 6-m-thick frozen kidney sections on day 20 by immunohistochemistry using the same protocol as for CD86 detection (described above). Rat anti-mouse Ki-67 mAb (DakoCytomation) was used to detect proliferating cells. Isotype control rat IgG2a (Pharmingen) served as a negative control. A minimum of 20 glomeruli/animal were examined to determine the number of Ki-67ϩ (proliferating) cells per gcs.
Statistical Analyses
Results are expressed as the mean Ϯ SEM. Unpaired t test was used for statistical analysis (GraphPad Prism; GraphPad Software Inc., San Diego, CA). Differences were considered to be statistically significant at P Ͻ 0.05.
Results
Glomerular Expression of CD80 and CD86 in Mice with Anti-GBM GN
Immunohistochemical staining showed that CD80 and CD86 were strongly and differentially expressed in kidneys of mice with anti-GBM GN (Figure 1 , C through F), whereas they were absent from kidneys of nondiseased mice ( Figure 1, A and B) . 
Crescentic GN in Mice Treated with Control Ab
Control Ab-treated mice developed crescentic GN with the mean crescent score ranging from 17.6 Ϯ 2.2 to 29.6 Ϯ 2.0% (Figures 3 and 4A ) and proteinuria ranging from 11.1 Ϯ 1.6 to 13.6 Ϯ 1.5 mg/24 h ( Figure 5 ). Nondiseased mice had an average proteinuria of 1.6 Ϯ 0.2 mg/24 h. Control Ab-treated mice also had significant numbers of CD4ϩ T cells (means ranging from 0.49 Ϯ 0.09 to 0.73 Ϯ 0.03 c/gcs; Figure 6 ) and macrophages (means ranging from 2.6 Ϯ 0.1 to 4.4 Ϯ 0.1 c/gcs; Figure 7 ) in glomeruli.
Effect of Anti-CD80 and/or Anti-CD86 mAb Treatment on Disease Outcome and Immune Responses
Renal Injury. Anti-CD80 or anti-CD86 mAb treatment did not alter crescent formation (Figures 3, A and B, and 4, A through C) or proteinuria ( Figure 5, A and B) . In contrast, crescent formation (29.6 Ϯ 2.0 versus 13.6 Ϯ 1.7%; P ϭ 0.0001; Figures 3C and 4 , A and D) and proteinuria (13.6 Ϯ 1.5 versus 8.8 Ϯ 1.2 mg/24 h; P ϭ 0.03; Figure 5C ) were markedly attenuated by inhibiting both CD80 and CD86 compared with controls, which was confirmed by a separate anti-CD80/86 experiment. Figure 8C ). This was confirmed by a separate anti-CD80/86 experiment.
Glomerular Adhesion Molecules. P-selectin was absent from kidneys of nondiseased mice but was strongly upregulated within glomeruli of mice with anti-GBM GN ( Figures 9A  and 10, A and B) . ICAM-1 was constitutively expressed in nondiseased mice in interstitial and glomerular (intra and peri) areas and was upregulated in mice with GN ( Figures 9B and 10,  D and E) . Administration of anti-CD80/86 mAb significantly reduced intraglomerular expression of P-selectin (2.1 Ϯ 0.3 Figure 1 . Expression of CD80 and CD86 in kidneys of mice with anti-glomerular basement membrane (anti-GBM) glomerulonephritis (GN). CD80 and CD86 were identified in 6-m-thick frozen kidney sections by immunohistochemistry using the ABC technique and diaminobenzidine to detect positive cells (brown). CD80 and CD86 are not present in kidneys of normal, nondiseased mice (A and B) but are upregulated in kidneys of mice with GN (C through F). CD80 is expressed in glomerular (intra and peri) and interstitial regions (C and D), whereas CD86 is expressed only within glomeruli and in perivascular regions (E and F). Magnification, ϫ100 in A, C, and E; ϫ400 in B, D, and F. Figures 9B and 10F) .
Renal Cytokines, Chemokines, and Chemokine Receptors. Renal mRNA levels of IFN-␥, MIF, and IL-1␤ were upregulated in mice that had anti-GBM GN and received control Ab compared with nondiseased mice. mRNA levels of IFN-␥ and MIF were markedly reduced by the anti-CD80/86 mAb treatment; however, IL-1␤ was increased (Table 1) . mRNA levels of chemokines and chemokine receptors were either not significantly Systemic Th1/Th2 Balance. Production of IFN-␥ by cultured splenocytes was not significantly affected by anti-CD80 or anti-CD86 mAb treatment, whereas anti-CD80/86 Ab treatment caused a trend toward increased IFN-␥ production ( Table  2) . Splenocyte production of IL-4 ( Table 2 ) and serum levels of Ag-specific IgG1 and IgG2a (Table 3) were also not significantly affected by any treatment.
Discussion
The current studies demonstrate a local role for CD80 and CD86 in glomerular T cell-mediated effector responses that induce crescentic anti-GBM GN. They show that CD80 and CD86 are strongly upregulated in glomeruli of mice with anti-GBM GN, in which they enhance glomerular recruitment of Th1 effectors and macrophages without affecting the systemic Th1/Th2 balance. Furthermore, they demonstrate that the increased number of effector leukocytes in glomeruli is associated with upregulation of intraglomerular adhesion molecules Pselectin and ICAM-1 and renal proinflammatory cytokines IFN-␥ and MIF.
We first demonstrated that CD80 and CD86 both are prominently expressed in glomeruli of mice with anti-GBM GN, whereas they are absent in kidneys of nondiseased mice. We also showed that CD80 is expressed by both infiltrating macrophages and intrinsic mesangial cells in nephritic glomeruli, whereas CD86 is absent from infiltrating leukocytes but might be expressed by glomerular endothelial cells. Similarly, compared with normal individuals, humans with Th1-like crescentic GN have enhanced renal expression of CD80, as well as increased numbers of CD86ϩ cells in glomeruli positively correlating with CD4ϩ T cell infiltration (24) . The upregulation of CD80 and CD86 in inflamed glomeruli suggested that the expression of these molecules by both infiltrating leukocytes and Figure 9 . Intraglomerular expression of P-selectin and CAM-1 in mice with GN receiving control Ab or anti-CD80 and CD86 mAb. P-selectin and intercellular adhesion molecule-1 (ICAM-1) expression was detected by immunofluorescence and scored semiquantitatively from 0 (background staining) to 3 (very strong staining). Results are expressed as the mean score Ϯ SEM. Expression of P-selectin (A) and ICAM-1 (B) within glomeruli of mice that received anti-CD80/86 mAb was markedly reduced compared with control Ab-treated mice. Dotted line represents glomerular expression of ICAM-1 in normal mice without GN. P-selectin was absent from kidneys of normal mice. **P ϭ 0.006; ***P ϭ 0.0007. Figure 10 . Representative photomicrographs of P-selectin and ICAM-1 expression in glomeruli of mice that had GN and received control Ab or anti-CD80 and CD86 mAb. P-selectin and ICAM-1 expression was detected on 6-m-thick frozen kidney sections by immunofluorescence. P-selectin is absent from kidneys of normal mice without GN (A) but is expressed within glomeruli of mice that had GN and received control Ab (B). ICAM-1 is upregulated in glomeruli of mice that had GN and were treated with control Ab (E) compared with normal mice without GN (D). Administration of anti-CD80/86 mAb significantly reduced intraglomerular expression of P-selectin (C) and ICAM-1 (F). Magnification, ϫ400.
intrinsic glomerular cells may be important in local glomerular T cell effector responses that induce crescentic GN. To test this hypothesis, we used accelerated anti-GBM GN (because the development of GN in this model occurs in two phases, the induction and the effector phases, as described in the introduction), and control or neutralizing anti-CD80 and/or anti-CD86 mAb were administered to mice only during the effector phase, after the systemic immune response had been established.
The development of anti-GBM GN is mediated by infiltrating CD4ϩ Th1 cells and macrophages (1-3) . The inhibition of CD80 or CD86 did not affect CD4ϩ T cell and macrophage accumulation in glomeruli or renal injury. Blockade of both CD80 and CD86, however, significantly attenuated glomerular infiltration of CD4ϩ T cells and macrophages, resulting in decreased renal injury. The ratio of T cells to macrophages in glomeruli was not altered by the anti-CD80/86 mAb treatment, suggesting that T cell-directed macrophage recruitment to glomeruli was not affected. However, the possibility that macrophages were insufficiently activated, thus contributing to attenuated renal injury, is not excluded. These results suggest that CD80 and CD86 have overlapping roles in facilitating glomerular accumulation of CD4ϩ Th1 effectors and macrophages and that co-stimulation provided by either of these molecules is adequate for full expression of crescentic anti-GBM GN. CD80 and/or CD86 previously has been blocked in the same model of GN (20) , in which inhibition of CD80 reduced disease, blockade of CD86 exacerbated injury, and neutralization of both CD80 and CD86 had no effect on disease development. However, in those experiments, these molecules were blocked during the induction phase of the disease, in which they play a different role compared with the effector phase, thus producing different results to those of the current study.
Studies in IFN-␥-deficient (28) and IL-4 -deficient mice (5) have shown that glomerular accumulation of CD4ϩ T cells and macrophages and subsequent development of crescentic anti-GBM GN are exacerbated by IFN-␥ and attenuated by IL-4. Numerous studies have demonstrated that CD80/86 co-stimulation can alter the Th1/Th2 balance and affect disease outcome (12, 13, 29) . In the current study, because the administration of anti-CD80 and/or CD86 mAb commenced after the systemic immune response had been well established, the systemic Th1/ Th2 balance, as assessed by splenocyte production of IFN-␥ and IL-4 and circulating IgG1 and IgG2a levels, was not significantly affected by any of the treatments. In fact, blockade of CD80 and CD86 resulted in a nonstatistically significant increase in splenocyte IFN-␥ production, suggesting that decreased glomerular presence of CD4ϩ T cells and macrophages in mice that were treated with anti-CD80/86 mAb cannot be attributed to a defect in the generation of Th1 effectors but that CD80 and CD86 locally play a role in promoting glomerular accumulation of Th1 cells and macrophages.
Ag-specific cutaneous DTH, also known to be mediated by recruited CD4ϩ Th1 cells and macrophages, was unaffected in mice that received anti-CD80 or anti-CD86 mAb treatment but Previous studies have also demonstrated that CD80 and CD86 can enhance migration of effector T cells into the target tissue and exacerbate disease. As already mentioned, in experimental chronic renal allograft rejection, blockade of CD28/B7 co-stimulation late after the onset of graft injury attenuated intragraft accumulation of T cells and macrophages and improved graft function (23) . In addition, adoptive transfer of sensitized encephalitogenic T cells into CD80/86Ϫ/Ϫ mice markedly reduced clinical signs of EAE, which was associated with reduced leukocyte infiltration into the target tissue (11) . Similarly, CD28Ϫ/Ϫ mice failed to develop clinical signs of EAE without affecting proliferation or Th1 cytokine production by Ag-specific T cells (30) . However, both central nervous system inflammation and DTH responses to the immunizing Ag were significantly reduced, suggesting that disruption of the CD28/B7 pathway decreased trafficking of pathogenic T cells into the target organ. Moreover, blockade of both CD80 and CD86 in recipient mice of previously sensitized splenocytes suppressed the development of EAT by diminishing infiltration of T cells into the thyroid (14) .
The mechanisms by which CD80 and CD86 may locally promote glomerular accumulation of Th1 effectors and macrophages and consequently enhance renal injury are unknown; however, several non-mutually exclusive possibilities exist. Co-stimulation provided by CD80 and CD86 might enhance the initial infiltration of T cells and macrophages into glomeruli by upregulating glomerular expression of adhesion molecules. Pselectin and ICAM-1 are upregulated on activated endothelium and are known to mediate the initial migration of effector Th1 cells and macrophages into inflamed tissue (31) (32) (33) . Both of these adhesion molecules are upregulated in glomeruli of animals with crescentic anti-GBM GN and mediate glomerular infiltration of leukocytes (25,34 -36) . Inhibition of P-selectin in anti-GBM GN prevents the development of disease by reducing glomerular T cell and/or macrophage recruitment (25, 36) , and attenuated renal injury in ICAM-1Ϫ/Ϫ mice is associated with reduced glomerular leukocyte infiltration (34) . Previous reports have demonstrated that enhanced T cell influx into inflamed tissue (psoriatic skin lesions) as a result of CD80/86 co-stimulation can be associated with increased endothelial expression of P-selectin and ICAM-1 (37) . In this study, we demonstrated that P-selectin and ICAM-1 are strongly upregulated in glomeruli of mice that develop anti-GBM GN. Inhibition of CD80 and CD86 markedly attenuated intraglomerular expression of Pselectin and ICAM-1, correlating with reduced accumulation of CD4ϩ T cells and macrophages. These results suggest that CD80 and CD86 might enhance the initial glomerular infiltration of Th1 effectors and macrophages by upregulating local adhesion molecules that these leukocytes need to migrate into the target tissue and mediate disease. However, it is still unknown whether the downregulation of adhesion molecules as a result of CD80/86 blockade is a cause or a consequence of reduced intraglomerular leukocyte numbers and renal injury.
CD28/B7 co-stimulation may also alter renal expression of proinflammatory cytokines, such as IFN-␥, MIF, and IL-1␤, which are upregulated in crescentic anti-GBM GN and promote glomerular accumulation of T cells and macrophages, leading to exacerbated disease development (38 -41) . CD80/86 co-stimulation was demonstrated previously to affect the expression of cytokines in the target organ of mice that develop chronic renal allograft rejection, as well as in animals with EAE, and alter disease (12, 37) . In this study, reduced glomerular recruitment of CD4ϩ T cells and macrophages and attenuated renal injury as a result of the inhibition of CD80 and CD86 correlated with decreased renal IFN-␥ and MIF mRNA levels, suggesting an additional mechanism by which CD80 and CD86 might locally promote glomerular accumulation of CD4ϩ T cells and macrophages and subsequent renal injury. It is possible, however, that decreased renal cytokine expression is a consequence rather than a cause of reduced glomerular presence of T cells and macrophages. It is interesting that the amount of IL-1␤ mRNA in the kidneys of mice that received anti-CD80/86 mAb was increased. The reason for this is not known; however, attenuated severity of EAE as a result of the blockade of CD80 and CD86 also correlated with inhibition of Th1 cytokines (IL-2 and IFN-␥) and upregulation of IL-1␤ in the target organ (12) .
CD80/86 co-stimulation may alter the expression of chemokines, such as MCP-1, RANTES, IP-10, and MIP-1␣, in the kidney and/or chemokine receptors, such as CCR5, CXCR3, CCR2, and CCR5, on Th1 effectors and macrophages that might be important for these cells to migrate into glomeruli and mediate disease (33, (42) (43) (44) (45) . CD80 and CD86 were shown previously to affect the expression of chemokines (MIP-1␣ and MIP-1␤) (46) and chemokine receptors (CCR5) (47) . Our results, however, show that attenuated glomerular accumulation of T cells and macrophages cannot be explained by reduced levels of chemokines or chemokine receptors in the kidney because they were either unaffected or increased by inhibiting CD80 and CD86. A possible reason for the upregulation of chemokines (MCP-1 and IP-10) in the kidneys of mice that received anti-CD80/86 mAb is the increased renal expression of IL-1␤ because this cytokine has been shown to upregulate these chemoattractants (45, 48) . In addition, increased renal CCR5 expression as a result of B7 blockade is consistent with previous evidence demonstrating downregulation of this chemokine receptor after CD28-mediated signaling (47) .
CD80 and CD86 might also enhance expansion and survival of Th1 effectors and macrophages in glomeruli. Assessment of intraglomerular proliferation and apoptosis on day 20, however, shows that neither of these mechanisms is associated with decreased leukocyte accumulation in glomeruli of mice that received anti-CD80/86 Ab. This is not surprising, because activation, proliferation, and apoptosis of naïve but not effector CD4ϩ T cells have been shown to be dependent on CD80/86 co-stimulation (8) . However, the possibility that glomerular proliferation and survival were decreased at earlier time points of the disease, thus contributing to reduced leukocyte accumulation in the kidney, is not excluded. It is noted that glomerular apoptosis was not increased in nephritic compared with nondiseased glomeruli. Previous experiments in the same model of GN have shown a similar result (2) . In contrast, glomerular proliferation was prominent in diseased glomeruli, suggesting that the disease at this time point (day 20) is at the proliferative rather than the apoptotic stage, which occurs during the more chronic phases of GN, when renal fibrosis and scarring occur (49) .
Our studies demonstrate, for the first time, that CD80 and CD86 co-stimulatory molecules are upregulated in glomeruli of mice that develop crescentic anti-GBM GN, in which they play an important role in local nephritogenic T cell effector responses. CD80 and CD86 both promote glomerular accumulation of CD4ϩ Th1 effectors and macrophages, associated with upregulation of adhesion molecules P-selectin and ICAM-1 and pathogenic proinflammatory cytokines IFN-␥ and MIF in the target tissue, leading to disease exacerbation. Enhanced expression of CD80 and CD86 correlating with CD4ϩ T cell recruitment in the kidneys of patients with Th1-like crescentic GN suggests that these co-stimulatory molecules are potential therapeutic targets for the treatment of rapidly progressive human nephritis.
